[시장보고서]암 줄기세포 시장 분석 및 예측(-2035년) : 유형별, 제품 유형별, 서비스별, 기술별, 용도별, 최종 사용자별, 프로세스별, 디바이스별, 솔루션별

암 줄기세포 시장 분석 및 예측(-2035년) : 유형별, 제품 유형별, 서비스별, 기술별, 용도별, 최종 사용자별, 프로세스별, 디바이스별, 솔루션별

Cancer Stem Cells Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Device, Solutions

상품코드 : 1954347

리서치사 : Global Insight Services

발행일 : 2026년 02월

페이지 정보 : 영문 300 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,750

￦ 7,170,000

PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF, Excel 이용 범위와 동일합니다.

US $ 5,750

￦ 8,679,000

PDF & Excel (Site License)

PDF, Excel 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다.

US $ 6,750

￦ 10,189,000

PDF & Excel (Enterprise License)

PDF, Excel 보고서를 동일 기업의 전 세계 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF, Excel 이용 범위와 동일합니다.

한글목차

샘플 요청 목록에 추가

세계의 암 줄기세포 시장은 2024년 39억 달러에서 2034년까지 84억 달러로 확대되어 CAGR 약 7.3%를 나타낼 것으로 예측됩니다. 암 줄기세포 시장은 종양 내에 존재하며, 자가 재생 능력을 가지고 암의 진행과 전이를 촉진하는 세포에 초점을 맞추었습니다. 이 시장은 종양의 재발을 예방하고 치료 효과를 향상시키기 위해 이러한 세포를 표적으로 하는 치료법을 포함합니다. 바이오테크놀러지의 진보와 암 이환율 증가가 시장 성장을 견인하고 있으며, 암 줄기세포를 효과적으로 억제하기 위한 혁신적 치료법이나 맞춤형 의료 접근의 필요성이 강조되고 있습니다.

암 줄기세포 시장은 암 연구와 표적요법의 진보에 견인되어 대폭적인 성장이 예상되고 있습니다. 부문별로, 치료제 하위 부문은 특히 단일클론항체 및 저분자 억제제에서 최고 성능을 나타냅니다. 이러한 치료법은 암 줄기세포 경로를 표적으로 하는데 있어서 매우 중요하며, 유망한 치료 성과를 가져옵니다. 진단 하위 부문은 이어서 바이오마커의 확인과 영상 기술이 조기 발견과 개인화 치료 전략에서 중요한 역할을 합니다. 세포 기반 분석 분야는 시험관 내 시험 및 약물 스크리닝 수요 증가를 반영하여 기세를 늘리고 있습니다. 또한 기존 요법과 신규 암 줄기세포 표적 접근을 통합한 병용 요법의 대두도 주목할 만합니다. 이 추세는 종합적인 치료 요법으로 시장 변화를 뒷받침합니다. 바이오의약품 기업과 연구기관 간의 연구개발투자 및 제휴는 혁신을 가속화하고, 이 진화하는 환경에서 이해관계자를 위한 수익성 높은 기회를 부각시키고 있습니다.

시장 세분화
유형	세포 유형, 종양 유형
제품	세포주, 기구, 소모품, 키트
서비스	세포 배양 서비스, 바이오 뱅킹 서비스, 동결보존
기술	세포 분리 기술, 세포 분석 기술
응용 분야	조사용도, 임상용도, 중개 연구, 신약개발
최종 사용자	생명 공학 회사, 제약 회사, 연구 기관, 병원 및 클리닉
프로세스	In Vivo, In Vitro, Ex Vivo
장비	세포 분류 장치, 유동 세포 분석
솔루션	암 줄기세포 분석, 암 줄기세포 마커

암 줄기세포 시장은 가격 전략과 혁신적인 제품 출시의 영향으로 시장 점유율이 변동하는 역동적인 변화를 경험하고 있습니다. 각사는 경쟁력 있는 가격 설정에 의해 점유율 확대를 도모하는 것과 동시에 신제품의 발매에 의해 치료 옵션의 확충을 진행하고 있습니다. 시장 상황은 치료효과와 환자 결과 향상을 목적으로 한 연구개발의 급증이 특징이며, 이에 따라 규제 승인 대기 제품 파이프라인이 충실해 시장은 대폭적인 성장이 전망되고 있습니다. 전략적 제휴와 공동 연구가 시장의 기세를 한층 더 가속시켜, 첨단 암 줄기세포 치료로 길을 열고 있습니다. 경쟁 벤치마킹 관점에서 기존 기업은 광범위한 제품 포트폴리오를 활용하여 경쟁 우위를 유지하고 있습니다. 신흥기업은 혁신적인 기술과 전략적 제휴를 통해 시장에 진출하고 있습니다. 규제의 영향은 매우 중요하며 엄격한 지침이 제품 개발과 시장 진입에 영향을 미칩니다. 북미와 유럽은 유리한 규제 체제로 최첨단에 위치하고 있지만, 아시아태평양은 증가하는 투자와 지원적인 정부 정책에 힘입어 수익성이 높은 시장으로 부상하고 있습니다. 경쟁 구도는 고도로 분단되고 있으며 연구개발의 지속적인 진전이 시장을 진전시키고 있습니다. 시장 진출기업은 세계의 사업 전개를 확대하기 위해 전략적인 인수합병에 주력하고 있습니다.

주요 동향과 촉진요인:

암 줄기세포 시장은 암 연구와 맞춤형 의료의 진보에 견인되어 변혁적인 성장을 이루고 있습니다. 주요 동향으로서 암 줄기세포에 특화된 표적요법에 대한 주목이 높아지고 있어 보다 효과적인 치료성과가 기대되고 있습니다. 이 전환은 유전체학나 단백질체학에서의 기술적 진보에 의해 암 줄기세포의 생물학에 대한 깊은 인사이트를 얻을 수 있는 것으로 지원되고 있습니다. 게다가 세계적으로 암 이환율이 증가하고 있는 것이 시장 수요를 뒷받침하고 있습니다. 암 발생률이 상승을 계속하는 가운데, 생존율과 생활의 질을 향상시키는 혁신적 치료법에 대한 긴급성은 높아지고 있습니다. 또 다른 촉진요인은 공적 및 민간 부문 양방에 의한 암 연구에 대한 투자 확대이며, 이들이 신규 치료법의 개발을 촉진하고 있습니다. 또한 바이오테크놀러지 기업과 학술기관의 연계에 의해 연구 성과의 임상 응용 전환이 가속화되고 있습니다. 이러한 파트너십은 의약품 개발 및 규제 당국의 승인과 관련된 과제를 극복하는 데 매우 중요합니다. 시장은 또한 제품 포트폴리오를 확대하고 R&D 능력을 강화하기 위한 전략적 제휴와 합병도 증가하고 있습니다. 암 줄기세포에 대한 이해가 깊어짐에 따라, 암 치료의 패러다임을 재정의하는 획기적인 치료법을 개발할 기회가 기업에서 많이 태어나고 있습니다.

시장 규모 및 예측 : 유형별
- 세포 유형
- 종양 유형
시장 규모 및 예측 : 제품별
- 세포주
- 기구
- 소모품
- 키트
시장 규모 및 예측 : 서비스별
- 세포 배양 서비스
- 바이오뱅킹 서비스
- 동결보존
시장 규모 및 예측 : 기술별
- 세포 분리 기술
- 세포 분석 기술
시장 규모 및 예측 : 용도별
- 조사 용도
- 임상 용도
- 중개 연구
- 신약 개발
시장 규모 및 예측 : 최종 사용자별
- 바이오테크놀러지 기업
- 제약기업
- 연구기관
- 병원 및 진료소
시장 규모 및 예측 : 프로세스별
- In vivo
- In vitro
- Ex Vivo
시장 규모 및 예측 : 디바이스별
- 세포 분류 장치
- 유동 세포 분석
시장 규모 및 예측 : 솔루션별
- 암 줄기세포 분석
- 암 줄기세포 마커

제5장 지역별 분석

북미
- 미국
- 캐나다
- 멕시코
라틴아메리카
- 브라질
- 아르헨티나
- 기타 라틴아메리카
아시아태평양
- 중국
- 인도
- 한국
- 일본
- 호주
- 대만
- 기타 아시아태평양
유럽
- 독일
- 프랑스
- 영국
- 스페인
- 이탈리아
- 기타 유럽
중동 및 아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 남아프리카
- 사하라 이남 아프리카
- 기타 중동 및 아프리카

제6장 시장 전략

수요 및 공급의 갭 분석
무역 및 물류상의 제약
가격, 비용, 마진의 동향
시장 침투
소비자 분석
규제 개요

제7장 경쟁 정보

시장 포지셔닝
시장 점유율
경쟁 벤치마킹
주요 기업의 전략

제8장 기업 프로파일

Stemline Therapeutics
Onco Med Pharmaceuticals
Verastem
Asterias Biotherapeutics
Stemcentrx
Oncolys Bio Pharma
Caladrius Biosciences
Cytori Therapeutics
Epicent Rx
Tiziana Life Sciences
Immuno Cellular Therapeutics
Oryzon Genomics
Bio Time
Epizyme
Karyopharm Therapeutics
Fortress Biotech
Neuralstem
Bio Eclipse Therapeutics
Agenus
Cellectar Biosciences

제9장 당사에 대해서

JHS

영문 목차

영문목차

Cancer Stem Cells Market is anticipated to expand from $3.9 billion in 2024 to $8.4 billion by 2034, growing at a CAGR of approximately 7.3%. The Cancer Stem Cells Market focuses on cells within tumors that possess the ability to self-renew and drive cancer progression and metastasis. This market encompasses therapies targeting these cells to prevent tumor recurrence and improve treatment efficacy. Advances in biotechnology and increasing cancer prevalence drive market growth, emphasizing the need for innovative treatments and personalized medicine approaches to effectively combat cancer stem cells.

The Cancer Stem Cells Market is poised for significant growth, driven by advancements in cancer research and targeted therapies. Among the segments, the therapeutics sub-segment emerges as a top performer, particularly in monoclonal antibodies and small molecule inhibitors. These therapies are pivotal in targeting cancer stem cell pathways, offering promising treatment outcomes. The diagnostics sub-segment follows closely, with biomarker identification and imaging technologies playing a crucial role in early detection and personalized treatment strategies. The cell-based assays segment is gaining momentum, reflecting the increasing demand for in vitro testing and drug screening. Furthermore, the rise of combination therapies, integrating traditional treatments with novel cancer stem cell-targeted approaches, is noteworthy. This trend underscores the market's shift towards comprehensive treatment regimens. Investments in R&D and collaborations between biopharmaceutical companies and research institutions are accelerating innovation, highlighting lucrative opportunities for stakeholders in this evolving landscape.

Market Segmentation
Type	Cell Type, Tumor Type
Product	Cell Lines, Instruments, Consumables, Kits
Services	Cell Culture Services, Biobanking Services, Cryopreservation
Technology	Cell Separation Technology, Cell Analysis Technology
Application	Research Applications, Clinical Applications, Translational Research, Drug Discovery
End User	Biotechnology Companies, Pharmaceutical Companies, Research Institutes, Hospitals and Clinics
Process	In Vivo, In Vitro, Ex Vivo
Device	Cell Sorters, Flow Cytometers
Solutions	Cancer Stem Cell Assays, Cancer Stem Cell Markers

The Cancer Stem Cells Market is witnessing a dynamic shift, with market share being influenced by pricing strategies and innovative product launches. Companies are focusing on competitive pricing to capture a larger share, while new product launches are enhancing therapeutic options. The market landscape is characterized by a surge in research and development, aimed at improving treatment efficacy and patient outcomes. This has led to a robust pipeline of products awaiting regulatory approval, positioning the market for significant growth. The strategic alliances and collaborations are further driving market momentum, paving the way for advanced cancer stem cell therapies. In terms of competition benchmarking, established players are leveraging their extensive portfolios to maintain a competitive edge. Emerging companies are entering the market with novel technologies and strategic partnerships. Regulatory influences are pivotal, with stringent guidelines impacting product development and market entry. North America and Europe are at the forefront due to favorable regulatory frameworks, while Asia-Pacific is emerging as a lucrative market, driven by increasing investments and supportive government policies. The competitive landscape is highly fragmented, with continuous advancements in research propelling the market forward. Market participants are focusing on strategic mergers and acquisitions to expand their global footprint.

Geographical Overview:

The Cancer Stem Cells Market is witnessing dynamic growth across various regions, each presenting unique opportunities. North America leads, driven by advanced research facilities and substantial investments in biotechnology. The presence of major pharmaceutical companies further accelerates market expansion. Europe follows, with robust government support for cancer research and a strong focus on innovative therapies. The region's regulatory framework enhances market growth. In Asia Pacific, rapid economic development and increasing healthcare expenditure fuel market expansion. Countries like China and India are emerging as key players, investing heavily in cancer research. The growing prevalence of cancer in these regions also drives demand. Latin America and the Middle East & Africa are nascent markets with significant potential. In Latin America, improved healthcare infrastructure and rising awareness contribute to market growth. Meanwhile, the Middle East & Africa are recognizing the importance of investing in advanced cancer treatments to improve patient outcomes.

Global tariffs and geopolitical tensions are profoundly impacting the Cancer Stem Cells Market, particularly in Japan, South Korea, China, and Taiwan. Japan and South Korea are enhancing their biopharmaceutical capabilities to mitigate reliance on imports, while China is accelerating its domestic R&D to counteract Western restrictions. Taiwan, though a key player in biotech, faces geopolitical vulnerabilities. The global parent market for cancer treatments is robust, driven by technological advancements and increasing cancer incidences. By 2035, the market is anticipated to witness substantial growth, contingent upon strategic alliances and innovation. Concurrently, Middle East conflicts are influencing global supply chains, potentially escalating energy prices and impacting manufacturing costs across these nations, necessitating strategic energy procurement and supply chain resilience.

Key Trends and Drivers:

The Cancer Stem Cells Market is experiencing transformative growth, driven by advancements in cancer research and personalized medicine. A key trend is the increasing focus on targeted therapies that specifically address cancer stem cells, promising more effective treatment outcomes. This shift is supported by technological advancements in genomics and proteomics, enabling deeper insights into cancer stem cell biology. Additionally, the rising prevalence of cancer globally is propelling market demand. As cancer incidence continues to climb, there is a heightened urgency for innovative treatments that can improve survival rates and quality of life. Another driver is the growing investment in cancer research by both public and private sectors, fueling the development of novel therapeutic approaches. Furthermore, collaborations between biotech companies and academic institutions are accelerating the translation of research findings into clinical applications. These partnerships are pivotal in overcoming the challenges associated with drug development and regulatory approvals. The market is also witnessing an increase in strategic alliances and mergers, aimed at expanding product portfolios and enhancing R&D capabilities. As the understanding of cancer stem cells evolves, opportunities abound for companies to develop groundbreaking therapies that could redefine cancer treatment paradigms.

Research Scope:

Estimates and forecasts the overall market size across type, application, and region.
Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

1 Executive Summary

1.1 Market Size and Forecast
1.2 Market Overview
1.3 Market Snapshot
1.4 Regional Snapshot
1.5 Strategic Recommendations
1.6 Analyst Notes

2 Market Highlights

2.1 Key Market Highlights by Type
2.2 Key Market Highlights by Product
2.3 Key Market Highlights by Services
2.4 Key Market Highlights by Technology
2.5 Key Market Highlights by Application
2.6 Key Market Highlights by End User
2.7 Key Market Highlights by Process
2.8 Key Market Highlights by Device
2.9 Key Market Highlights by Solutions

3 Market Dynamics

3.1 Macroeconomic Analysis
3.2 Market Trends
3.3 Market Drivers
3.4 Market Opportunities
3.5 Market Restraints
3.6 CAGR Growth Analysis
3.7 Impact Analysis
3.8 Emerging Markets
3.9 Technology Roadmap
3.10 Strategic Frameworks
- 3.10.1 PORTER's 5 Forces Model
- 3.10.2 ANSOFF Matrix
- 3.10.3 4P's Model
- 3.10.4 PESTEL Analysis

4 Segment Analysis

4.1 Market Size & Forecast by Type (2020-2035)
- 4.1.1 Cell Type
- 4.1.2 Tumor Type
4.2 Market Size & Forecast by Product (2020-2035)
- 4.2.1 Cell Lines
- 4.2.2 Instruments
- 4.2.3 Consumables
- 4.2.4 Kits
4.3 Market Size & Forecast by Services (2020-2035)
- 4.3.1 Cell Culture Services
- 4.3.2 Biobanking Services
- 4.3.3 Cryopreservation
4.4 Market Size & Forecast by Technology (2020-2035)
- 4.4.1 Cell Separation Technology
- 4.4.2 Cell Analysis Technology
4.5 Market Size & Forecast by Application (2020-2035)
- 4.5.1 Research Applications
- 4.5.2 Clinical Applications
- 4.5.3 Translational Research
- 4.5.4 Drug Discovery
4.6 Market Size & Forecast by End User (2020-2035)
- 4.6.1 Biotechnology Companies
- 4.6.2 Pharmaceutical Companies
- 4.6.3 Research Institutes
- 4.6.4 Hospitals and Clinics
4.7 Market Size & Forecast by Process (2020-2035)
- 4.7.1 In Vivo
- 4.7.2 In Vitro
- 4.7.3 Ex Vivo
4.8 Market Size & Forecast by Device (2020-2035)
- 4.8.1 Cell Sorters
- 4.8.2 Flow Cytometers
4.9 Market Size & Forecast by Solutions (2020-2035)
- 4.9.1 Cancer Stem Cell Assays
- 4.9.2 Cancer Stem Cell Markers

5 Regional Analysis

5.1 Global Market Overview
5.2 North America Market Size (2020-2035)
- 5.2.1 United States
  - 5.2.1.1 Type
  - 5.2.1.2 Product
  - 5.2.1.3 Services
  - 5.2.1.4 Technology
  - 5.2.1.5 Application
  - 5.2.1.6 End User
  - 5.2.1.7 Process
  - 5.2.1.8 Device
  - 5.2.1.9 Solutions
- 5.2.2 Canada
  - 5.2.2.1 Type
  - 5.2.2.2 Product
  - 5.2.2.3 Services
  - 5.2.2.4 Technology
  - 5.2.2.5 Application
  - 5.2.2.6 End User
  - 5.2.2.7 Process
  - 5.2.2.8 Device
  - 5.2.2.9 Solutions
- 5.2.3 Mexico
  - 5.2.3.1 Type
  - 5.2.3.2 Product
  - 5.2.3.3 Services
  - 5.2.3.4 Technology
  - 5.2.3.5 Application
  - 5.2.3.6 End User
  - 5.2.3.7 Process
  - 5.2.3.8 Device
  - 5.2.3.9 Solutions
5.3 Latin America Market Size (2020-2035)
- 5.3.1 Brazil
  - 5.3.1.1 Type
  - 5.3.1.2 Product
  - 5.3.1.3 Services
  - 5.3.1.4 Technology
  - 5.3.1.5 Application
  - 5.3.1.6 End User
  - 5.3.1.7 Process
  - 5.3.1.8 Device
  - 5.3.1.9 Solutions
- 5.3.2 Argentina
  - 5.3.2.1 Type
  - 5.3.2.2 Product
  - 5.3.2.3 Services
  - 5.3.2.4 Technology
  - 5.3.2.5 Application
  - 5.3.2.6 End User
  - 5.3.2.7 Process
  - 5.3.2.8 Device
  - 5.3.2.9 Solutions
- 5.3.3 Rest of Latin America
  - 5.3.3.1 Type
  - 5.3.3.2 Product
  - 5.3.3.3 Services
  - 5.3.3.4 Technology
  - 5.3.3.5 Application
  - 5.3.3.6 End User
  - 5.3.3.7 Process
  - 5.3.3.8 Device
  - 5.3.3.9 Solutions
5.4 Asia-Pacific Market Size (2020-2035)
- 5.4.1 China
  - 5.4.1.1 Type
  - 5.4.1.2 Product
  - 5.4.1.3 Services
  - 5.4.1.4 Technology
  - 5.4.1.5 Application
  - 5.4.1.6 End User
  - 5.4.1.7 Process
  - 5.4.1.8 Device
  - 5.4.1.9 Solutions
- 5.4.2 India
  - 5.4.2.1 Type
  - 5.4.2.2 Product
  - 5.4.2.3 Services
  - 5.4.2.4 Technology
  - 5.4.2.5 Application
  - 5.4.2.6 End User
  - 5.4.2.7 Process
  - 5.4.2.8 Device
  - 5.4.2.9 Solutions
- 5.4.3 South Korea
  - 5.4.3.1 Type
  - 5.4.3.2 Product
  - 5.4.3.3 Services
  - 5.4.3.4 Technology
  - 5.4.3.5 Application
  - 5.4.3.6 End User
  - 5.4.3.7 Process
  - 5.4.3.8 Device
  - 5.4.3.9 Solutions
- 5.4.4 Japan
  - 5.4.4.1 Type
  - 5.4.4.2 Product
  - 5.4.4.3 Services
  - 5.4.4.4 Technology
  - 5.4.4.5 Application
  - 5.4.4.6 End User
  - 5.4.4.7 Process
  - 5.4.4.8 Device
  - 5.4.4.9 Solutions
- 5.4.5 Australia
  - 5.4.5.1 Type
  - 5.4.5.2 Product
  - 5.4.5.3 Services
  - 5.4.5.4 Technology
  - 5.4.5.5 Application
  - 5.4.5.6 End User
  - 5.4.5.7 Process
  - 5.4.5.8 Device
  - 5.4.5.9 Solutions
- 5.4.6 Taiwan
  - 5.4.6.1 Type
  - 5.4.6.2 Product
  - 5.4.6.3 Services
  - 5.4.6.4 Technology
  - 5.4.6.5 Application
  - 5.4.6.6 End User
  - 5.4.6.7 Process
  - 5.4.6.8 Device
  - 5.4.6.9 Solutions
- 5.4.7 Rest of APAC
  - 5.4.7.1 Type
  - 5.4.7.2 Product
  - 5.4.7.3 Services
  - 5.4.7.4 Technology
  - 5.4.7.5 Application
  - 5.4.7.6 End User
  - 5.4.7.7 Process
  - 5.4.7.8 Device
  - 5.4.7.9 Solutions
5.5 Europe Market Size (2020-2035)
- 5.5.1 Germany
  - 5.5.1.1 Type
  - 5.5.1.2 Product
  - 5.5.1.3 Services
  - 5.5.1.4 Technology
  - 5.5.1.5 Application
  - 5.5.1.6 End User
  - 5.5.1.7 Process
  - 5.5.1.8 Device
  - 5.5.1.9 Solutions
- 5.5.2 France
  - 5.5.2.1 Type
  - 5.5.2.2 Product
  - 5.5.2.3 Services
  - 5.5.2.4 Technology
  - 5.5.2.5 Application
  - 5.5.2.6 End User
  - 5.5.2.7 Process
  - 5.5.2.8 Device
  - 5.5.2.9 Solutions
- 5.5.3 United Kingdom
  - 5.5.3.1 Type
  - 5.5.3.2 Product
  - 5.5.3.3 Services
  - 5.5.3.4 Technology
  - 5.5.3.5 Application
  - 5.5.3.6 End User
  - 5.5.3.7 Process
  - 5.5.3.8 Device
  - 5.5.3.9 Solutions
- 5.5.4 Spain
  - 5.5.4.1 Type
  - 5.5.4.2 Product
  - 5.5.4.3 Services
  - 5.5.4.4 Technology
  - 5.5.4.5 Application
  - 5.5.4.6 End User
  - 5.5.4.7 Process
  - 5.5.4.8 Device
  - 5.5.4.9 Solutions
- 5.5.5 Italy
  - 5.5.5.1 Type
  - 5.5.5.2 Product
  - 5.5.5.3 Services
  - 5.5.5.4 Technology
  - 5.5.5.5 Application
  - 5.5.5.6 End User
  - 5.5.5.7 Process
  - 5.5.5.8 Device
  - 5.5.5.9 Solutions
- 5.5.6 Rest of Europe
  - 5.5.6.1 Type
  - 5.5.6.2 Product
  - 5.5.6.3 Services
  - 5.5.6.4 Technology
  - 5.5.6.5 Application
  - 5.5.6.6 End User
  - 5.5.6.7 Process
  - 5.5.6.8 Device
  - 5.5.6.9 Solutions
5.6 Middle East & Africa Market Size (2020-2035)
- 5.6.1 Saudi Arabia
  - 5.6.1.1 Type
  - 5.6.1.2 Product
  - 5.6.1.3 Services
  - 5.6.1.4 Technology
  - 5.6.1.5 Application
  - 5.6.1.6 End User
  - 5.6.1.7 Process
  - 5.6.1.8 Device
  - 5.6.1.9 Solutions
- 5.6.2 United Arab Emirates
  - 5.6.2.1 Type
  - 5.6.2.2 Product
  - 5.6.2.3 Services
  - 5.6.2.4 Technology
  - 5.6.2.5 Application
  - 5.6.2.6 End User
  - 5.6.2.7 Process
  - 5.6.2.8 Device
  - 5.6.2.9 Solutions
- 5.6.3 South Africa
  - 5.6.3.1 Type
  - 5.6.3.2 Product
  - 5.6.3.3 Services
  - 5.6.3.4 Technology
  - 5.6.3.5 Application
  - 5.6.3.6 End User
  - 5.6.3.7 Process
  - 5.6.3.8 Device
  - 5.6.3.9 Solutions
- 5.6.4 Sub-Saharan Africa
  - 5.6.4.1 Type
  - 5.6.4.2 Product
  - 5.6.4.3 Services
  - 5.6.4.4 Technology
  - 5.6.4.5 Application
  - 5.6.4.6 End User
  - 5.6.4.7 Process
  - 5.6.4.8 Device
  - 5.6.4.9 Solutions
- 5.6.5 Rest of MEA
  - 5.6.5.1 Type
  - 5.6.5.2 Product
  - 5.6.5.3 Services
  - 5.6.5.4 Technology
  - 5.6.5.5 Application
  - 5.6.5.6 End User
  - 5.6.5.7 Process
  - 5.6.5.8 Device
  - 5.6.5.9 Solutions

6 Market Strategy

6.1 Demand-Supply Gap Analysis
6.2 Trade & Logistics Constraints
6.3 Price-Cost-Margin Trends
6.4 Market Penetration
6.5 Consumer Analysis
6.6 Regulatory Snapshot

7 Competitive Intelligence

7.1 Market Positioning
7.2 Market Share
7.3 Competition Benchmarking
7.4 Top Company Strategies

8 Company Profiles

8.1 Stemline Therapeutics
- 8.1.1 Overview
- 8.1.2 Product Summary
- 8.1.3 Financial Performance
- 8.1.4 SWOT Analysis
8.2 Onco Med Pharmaceuticals
- 8.2.1 Overview
- 8.2.2 Product Summary
- 8.2.3 Financial Performance
- 8.2.4 SWOT Analysis
8.3 Verastem
- 8.3.1 Overview
- 8.3.2 Product Summary
- 8.3.3 Financial Performance
- 8.3.4 SWOT Analysis
8.4 Asterias Biotherapeutics
- 8.4.1 Overview
- 8.4.2 Product Summary
- 8.4.3 Financial Performance
- 8.4.4 SWOT Analysis
8.5 Stemcentrx
- 8.5.1 Overview
- 8.5.2 Product Summary
- 8.5.3 Financial Performance
- 8.5.4 SWOT Analysis
8.6 Oncolys Bio Pharma
- 8.6.1 Overview
- 8.6.2 Product Summary
- 8.6.3 Financial Performance
- 8.6.4 SWOT Analysis
8.7 Caladrius Biosciences
- 8.7.1 Overview
- 8.7.2 Product Summary
- 8.7.3 Financial Performance
- 8.7.4 SWOT Analysis
8.8 Cytori Therapeutics
- 8.8.1 Overview
- 8.8.2 Product Summary
- 8.8.3 Financial Performance
- 8.8.4 SWOT Analysis
8.9 Epicent Rx
- 8.9.1 Overview
- 8.9.2 Product Summary
- 8.9.3 Financial Performance
- 8.9.4 SWOT Analysis
8.10 Tiziana Life Sciences
- 8.10.1 Overview
- 8.10.2 Product Summary
- 8.10.3 Financial Performance
- 8.10.4 SWOT Analysis
8.11 Immuno Cellular Therapeutics
- 8.11.1 Overview
- 8.11.2 Product Summary
- 8.11.3 Financial Performance
- 8.11.4 SWOT Analysis
8.12 Oryzon Genomics
- 8.12.1 Overview
- 8.12.2 Product Summary
- 8.12.3 Financial Performance
- 8.12.4 SWOT Analysis
8.13 Bio Time
- 8.13.1 Overview
- 8.13.2 Product Summary
- 8.13.3 Financial Performance
- 8.13.4 SWOT Analysis
8.14 Epizyme
- 8.14.1 Overview
- 8.14.2 Product Summary
- 8.14.3 Financial Performance
- 8.14.4 SWOT Analysis
8.15 Karyopharm Therapeutics
- 8.15.1 Overview
- 8.15.2 Product Summary
- 8.15.3 Financial Performance
- 8.15.4 SWOT Analysis
8.16 Fortress Biotech
- 8.16.1 Overview
- 8.16.2 Product Summary
- 8.16.3 Financial Performance
- 8.16.4 SWOT Analysis
8.17 Neuralstem
- 8.17.1 Overview
- 8.17.2 Product Summary
- 8.17.3 Financial Performance
- 8.17.4 SWOT Analysis
8.18 Bio Eclipse Therapeutics
- 8.18.1 Overview
- 8.18.2 Product Summary
- 8.18.3 Financial Performance
- 8.18.4 SWOT Analysis
8.19 Agenus
- 8.19.1 Overview
- 8.19.2 Product Summary
- 8.19.3 Financial Performance
- 8.19.4 SWOT Analysis
8.20 Cellectar Biosciences
- 8.20.1 Overview
- 8.20.2 Product Summary
- 8.20.3 Financial Performance
- 8.20.4 SWOT Analysis

9 About Us

9.1 About Us
9.2 Research Methodology
9.3 Research Workflow
9.4 Consulting Services
9.5 Our Clients
9.6 Client Testimonials
9.7 Contact Us